| Year |
Citation |
Score |
| 2023 |
Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. Author Correction: 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature. PMID 37626188 DOI: 10.1038/s41586-023-06446-1 |
0.326 |
|
| 2022 |
Sinha N, Sinha S, Valero C, Schaffer AA, Aldape K, Litchfield K, Chan TA, Morris LG, Ruppin E. Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types. Cancer Research. PMID 35385572 DOI: 10.1158/0008-5472.CAN-21-2542 |
0.3 |
|
| 2021 |
Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, Hoen DR, Mandal R, Setton J, Wu W, Shah R, ... ... Chan TA, et al. Mutations in and differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nature Cancer. 1: 1188-1203. PMID 33834176 DOI: 10.1038/s43018-020-00139-8 |
0.316 |
|
| 2020 |
Hakimi AA, Attalla K, DiNatale RG, Ostrovnaya I, Flynn J, Blum KA, Ged Y, Hoen D, Kendall SM, Reznik E, Bowman A, Hwee J, Fong CJ, Kuo F, Voss MH, ... Chan TA, et al. A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nature Communications. 11: 4168. PMID 32820162 DOI: 10.1038/S41467-020-17965-0 |
0.408 |
|
| 2020 |
Pitter KL, Casey DL, Lu YC, Hannum M, Zhang Z, Song X, Pecorari I, McMillan B, Ma J, Samstein RM, Pei IX, Khan AJ, Braunstein LZ, Morris LGT, Barker CA, ... ... Chan TA, et al. Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute. PMID 32726432 DOI: 10.1093/Jnci/Djaa095 |
0.378 |
|
| 2020 |
Katsoulakis E, Yu Y, Apte AP, Leeman JE, Katabi N, Morris L, Deasy JO, Chan TA, Lee NY, Riaz N, Hatzoglou V, Oh JH. Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. Oral Oncology. 110: 104877. PMID 32619927 DOI: 10.1016/J.Oraloncology.2020.104877 |
0.346 |
|
| 2020 |
Ged Y, Chaim JL, DiNatale RG, Knezevic A, Kotecha RR, Carlo MI, Lee CH, Foster A, Feldman DR, Teo MY, Iyer G, Chan T, Patil S, Motzer RJ, Hakimi AA, et al. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. Journal For Immunotherapy of Cancer. 8. PMID 32571992 DOI: 10.1136/Jitc-2019-000230 |
0.35 |
|
| 2020 |
Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, Ma X, Gong Y, Holland EC, Huse JT, Chan TA. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Science Advances. 6: eaaz3221. PMID 32494639 DOI: 10.1126/Sciadv.Aaz3221 |
0.403 |
|
| 2020 |
Takahashi H, Kawaguchi T, Yan L, Peng X, Qi Q, Morris LGT, Chan TA, Tsung A, Otsuji E, Takabe K. Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers. 12. PMID 32414098 DOI: 10.3390/Cancers12051221 |
0.317 |
|
| 2020 |
Srivastava RM, Purohit TA, Chan TA. Diverse Neoantigens and the Development of Cancer Therapies. Seminars in Radiation Oncology. 30: 113-128. PMID 32381291 DOI: 10.1016/J.Semradonc.2019.12.001 |
0.427 |
|
| 2020 |
Marcon J, DiNatale RG, Sanchez A, Kotecha RR, Gupta S, Kuo F, Makarov V, Sandhu A, Mano R, Silagy AW, Blum KA, Nassau DE, Benfante NE, Ortiz MV, Carlo MI, ... Chan TA, et al. Comprehensive genomic analysis of translocation renal cell carcinoma reveals copy number variations as drivers of disease progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32220885 DOI: 10.1158/1078-0432.Ccr-19-3283 |
0.331 |
|
| 2020 |
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal For Immunotherapy of Cancer. 8. PMID 32209603 DOI: 10.1136/Jitc-2019-000337 |
0.302 |
|
| 2020 |
Morris LG, Linxweiler M, Kuo F, Katabi N, Nadeem Z, Dalin MG, Makarov V, Chowell D, Dogan S, Ganly I, Hakimi AA, Wong RJ, Riaz N, Ho AL, Chan TA, et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32060100 DOI: 10.1158/1078-0432.Ccr-19-3758 |
0.333 |
|
| 2020 |
Li J, Wang W, Zhang Y, Cieślik M, Guo J, Tan M, Green MD, Wang W, Lin H, Li W, Wei S, Zhou J, Li G, Jing X, Vatan L, ... ... Chan TA, et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. The Journal of Clinical Investigation. PMID 32027624 DOI: 10.1172/Jci134402 |
0.427 |
|
| 2020 |
Attalla K, DiNatale RG, Reznik E, Fong C, Sanchez-Vega F, Silagy AW, Weng S, Coleman J, Lee C, Carlo MI, Russo P, Chan TA, Motzer RJ, Schultz ND, Voss MH, et al. Prevalence and landscape of actionable genomic alterations in renal cell carcinoma. Journal of Clinical Oncology. 38: 616-616. DOI: 10.1200/Jco.2020.38.6_Suppl.616 |
0.406 |
|
| 2020 |
Hakimi AA, Voss MH, Kuo F, Silagy AW, Marker M, Reising A, Millholland J, Chan TA, Russo P, Motzer RJ. Immune infiltration and angiogenesis as markers of outcome in the post-nephrectomy setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT). Journal of Clinical Oncology. 38: 5082-5082. DOI: 10.1200/Jco.2020.38.15_Suppl.5082 |
0.331 |
|
| 2020 |
Lin Y, Zhai S, Kuo F, Chan TA, Morris LG, Ferris RL, Faden DL, Ding F. Abstract PR05: APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Aacrahns19-Pr05 |
0.397 |
|
| 2019 |
Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, Kuo F, Morris LGT, Riaz N, Lenz TL, Chan TA. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nature Medicine. PMID 31700181 DOI: 10.1038/S41591-019-0639-4 |
0.348 |
|
| 2019 |
Heidegger S, Wintges A, Stritzke F, Bek S, Steiger K, Koenig PA, Göttert S, Engleitner T, Öllinger R, Nedelko T, Fischer JC, Makarov V, Winter C, Rad R, van den Brink MRM, ... ... Chan TA, et al. RIG-I activation is critical for responsiveness to checkpoint blockade. Science Immunology. 4. PMID 31519811 DOI: 10.1182/Blood-2019-128724 |
0.406 |
|
| 2019 |
Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J, Makarov V, Dalin MG, He J, Bailey M, Montesion M, Ross JS, Miller VA, Chan L, Ganly I, ... ... Chan TA, et al. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. The Journal of Clinical Investigation. PMID 31483290 DOI: 10.1172/Jci128227 |
0.37 |
|
| 2019 |
Faden DL, Ding F, Lin Y, Zhai S, Kuo F, Chan TA, Morris LG, Ferris RL. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. Oral Oncology. 96: 140-147. PMID 31422205 DOI: 10.1016/J.Oraloncology.2019.07.020 |
0.373 |
|
| 2019 |
Yang W, Morris LGT, Chan TA. Panel-based estimates of tumor mutational burden: characterizing unknown unknowns. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31410441 DOI: 10.1093/Annonc/Mdz234 |
0.326 |
|
| 2019 |
Lee M, Samstein RM, Valero C, Chan TA, Morris LGT. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Human Vaccines & Immunotherapeutics. 1-4. PMID 31361563 DOI: 10.1080/21645515.2019.1631136 |
0.413 |
|
| 2019 |
Sabio E, Chan TA. The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy. Genome Medicine. 11: 43. PMID 31340855 DOI: 10.1186/S13073-019-0661-7 |
0.384 |
|
| 2019 |
Wang J, Linxweiler M, Yang W, Chan TA, Morris LGT. Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. Oncotarget. 10: 3835-3839. PMID 31231463 DOI: 10.18632/Oncotarget.26982 |
0.347 |
|
| 2019 |
Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, Hakimi AA, Sonpavde G, Plimack E. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. Journal For Immunotherapy of Cancer. 7: 139. PMID 31138299 DOI: 10.1186/S40425-019-0621-1 |
0.347 |
|
| 2019 |
Morris LGT, Chan TA. Lung Cancer Evolution: What's Immunity Got to Do with It? Cancer Cell. 35: 711-713. PMID 31085173 DOI: 10.1016/J.Ccell.2019.04.009 |
0.376 |
|
| 2019 |
Mandal R, Samstein RM, Lee KW, Havel JJ, Wang H, Krishna C, Sabio EY, Makarov V, Kuo F, Blecua P, Ramaswamy AT, Durham JN, Bartlett B, Ma X, Srivastava R, ... ... Chan TA, et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science (New York, N.Y.). 364: 485-491. PMID 31048490 DOI: 10.1126/Science.Aau0447 |
0.389 |
|
| 2019 |
Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, ... ... Chan TA, et al. CD8 T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. PMID 31043744 DOI: 10.1038/S41586-019-1170-Y |
0.351 |
|
| 2019 |
Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, Chowell D, Makarov V, Hoen D, Dalin MG, Wexler L, Ghossein R, Katabi N, Nadeem Z, Cohen MA, Tian SK, ... ... Chan TA, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature Medicine. PMID 31011208 DOI: 10.1038/S41591-019-0434-2 |
0.439 |
|
| 2019 |
Wang Y, Yang J, Wild AT, Wu WH, Shah R, Danussi C, Riggins GJ, Kannan K, Sulman EP, Chan TA, Huse JT. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nature Communications. 10: 943. PMID 30808951 DOI: 10.1038/S41467-019-08905-8 |
0.315 |
|
| 2019 |
Casey DL, Pitter KL, Imber BS, Lin A, Chan TA, Beal K, Yamada Y, Feldman DR, Yang TJ. High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. Journal of Neuro-Oncology. PMID 30771201 DOI: 10.1007/S11060-019-03123-0 |
0.338 |
|
| 2019 |
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews. Cancer. PMID 30755690 DOI: 10.1038/S41568-019-0116-X |
0.355 |
|
| 2019 |
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, ... ... Chan TA, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics. PMID 30643254 DOI: 10.1038/S41588-018-0312-8 |
0.426 |
|
| 2019 |
Hakimi AA, Voss MH, Kuo F, Sanchez A, Liu M, Nixon BG, Vuong L, Ostrovnaya I, Chen YB, Reuter V, Riaz N, Cheng Y, Patel P, Marker M, Reising A, ... ... Chan TA, et al. Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer - Data from a Randomized Phase III Trial. Cancer Discovery. PMID 30622105 DOI: 10.1158/2159-8290.Cd-18-0957 |
0.401 |
|
| 2019 |
Hakimi AA, Ged Y, Flynn J, Hoen DR, Di Natale RG, Blum KA, Makarov V, Kuo F, Carlo MI, Lee C, Voss MH, Ostrovnaya I, Chan TA, Motzer RJ. The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB). Journal of Clinical Oncology. 37: 666-666. DOI: 10.1200/Jco.2019.37.7_Suppl.666 |
0.381 |
|
| 2019 |
Lee C, Natale RGD, Chowell D, Makarov V, Redzematovic A, Murray SJ, Carlo MI, Voss MH, Feldman DR, Motzer RJ, Chan TA, Hakimi AA. Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 37: 641-641. DOI: 10.1200/Jco.2019.37.7_Suppl.641 |
0.332 |
|
| 2019 |
Ged Y, Chaim J, Knezevic A, Carlo MI, Foster A, Feldman DR, Teo MY, Riaz N, Lee C, Patil S, Chan TA, Hakimi AA, Motzer RJ, Voss MH. Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts). Journal of Clinical Oncology. 37: 551-551. DOI: 10.1200/Jco.2019.37.7_Suppl.551 |
0.35 |
|
| 2019 |
Luksza M, Leung JP, Solovyov A, Redmond D, Merad M, Gnjatic S, Iacubuzio-Donohue C, DeMatteo RP, Chan TA, Wolchock J, Leach SD, Greenbaum BD, Merghoub T, Balachandran VP. Abstract IA34: Mapping immune recognition of non-self neoantigens in human pancreatic cancer Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Ia34 |
0.414 |
|
| 2019 |
Luksza M, Solovyov A, Vabret N, Balachandran V, Riaz N, Makarov V, Hellmann MD, Snyder A, Funt S, Remark R, Merad M, Gnjatic S, Bajorin DF, Rosenberg J, Leach S, ... ... Chan TA, et al. Abstract IA31: Measuring the emergence of non-self in tumors Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Ia31 |
0.375 |
|
| 2019 |
Rizvi N, Tang P, Bhardwaj N, Chan TA, Weber JS, Vickers M, Pintova S, Hirte H, Segal NH, Dhani N, Cho D, Chia S, Burns C, Tu D, Pearce L, et al. Abstract B207: Nivolumab +/- Ipilimumab in patients with hypermutated cancers detected in blood: NIMBLE Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-B207 |
0.416 |
|
| 2018 |
Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, Ojo NC, Caldwell K, Abhyankar J, Boucher T, Hart MG, ... ... Chan TA, et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nature Biotechnology. PMID 30556813 DOI: 10.1038/Nbt.4313 |
0.329 |
|
| 2018 |
Thulborn KR, Lu A, Atkinson IC, Pauliah M, Beal K, Chan TA, Omuro AMP, Yamada Y, Bradbury MS. Residual Tumor Volume, Cell Volume Fraction and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR imaging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30487127 DOI: 10.1158/1078-0432.Ccr-18-2079 |
0.319 |
|
| 2018 |
Voss MH, Reising A, Cheng Y, Patel P, Marker M, Kuo F, Chan TA, Choueiri TK, Hsieh JJ, Hakimi AA, Motzer RJ. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. The Lancet. Oncology. PMID 30416077 DOI: 10.1016/S1470-2045(18)30648-X |
0.334 |
|
| 2018 |
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30395155 DOI: 10.1093/Annonc/Mdy495 |
0.361 |
|
| 2018 |
Chan CS, Laddha SV, Lewis PW, Koletsky MS, Robzyk K, Da Silva E, Torres PJ, Untch BR, Li J, Bose P, Chan TA, Klimstra DS, Allis CD, Tang LH. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nature Communications. 9: 4158. PMID 30315258 DOI: 10.1038/S41467-018-06498-2 |
0.318 |
|
| 2018 |
Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Science Translational Medicine. 10. PMID 30232229 DOI: 10.1126/Scitranslmed.Aat7807 |
0.394 |
|
| 2018 |
Yamashita AS, da Costa Rosa M, Borodovsky A, Festuccia WT, Chan T, Riggins GJ. Demethylation and epigenetic modification with 5-Azacytidine reduces IDH1 mutant glioma growth in combination with Temozolomide. Neuro-Oncology. PMID 30184215 DOI: 10.1093/Neuonc/Noy146 |
0.342 |
|
| 2018 |
Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, Nanjangud G, Eng S, Bose P, Kuo F, Morris LGT, Landa I, Carrillo Albornoz PB, Riaz N, Nikiforov YE, ... ... Chan TA, et al. Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell. 34: 256-270.e5. PMID 30107176 DOI: 10.1016/J.Ccell.2018.07.002 |
0.375 |
|
| 2018 |
Lee CH, Yelensky R, Jooss K, Chan TA. Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. Trends in Immunology. PMID 29751996 DOI: 10.1016/J.It.2018.04.005 |
0.405 |
|
| 2018 |
Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, ... ... Chan TA, et al. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017769992. PMID 29683790 DOI: 10.1200/Jco.2017.76.9992 |
0.306 |
|
| 2018 |
Desrichard A, Kuo F, Chowell D, Lee KW, Riaz N, Wong RJ, Chan TA, Morris LGT. Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. Journal of the National Cancer Institute. PMID 29659925 DOI: 10.1093/Jnci/Djy060 |
0.35 |
|
| 2018 |
Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, et al. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nature Communications. 9: 1057. PMID 29535300 DOI: 10.1038/S41467-018-03476-6 |
0.367 |
|
| 2018 |
Voss MH, Kuo F, Sanchez A, Ostrovnaya I, Cheng Y, Patel P, Marker M, Reising A, Chan TA, Motzer RJ, Hakimi AA. Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis. Journal of Clinical Oncology. 36: 4515-4515. DOI: 10.1200/Jco.2018.36.15_Suppl.4515 |
0.312 |
|
| 2018 |
Laddha SV, Chan CS, Lewis P, Koletsky M, Robzyk K, Silva ED, Torres PJ, Untch B, Bose P, Chan T, Klimstra DS, Allis DC, Tang LH. Abstract 1799: ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct “alpha-cell signature” subgroup Cancer Research. 78: 1799-1799. DOI: 10.1158/1538-7445.Am2018-1799 |
0.364 |
|
| 2018 |
Wild A, Wang Y, Wu W, Haddock SL, Chan TA. Exploitation of 2-Hydroxyglutarate-Mediated Deficiency in Homologous Recombination with PARP Inhibition to Achieve Radiosensitization in IDH-Mutant Tumors International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.06.292 |
0.321 |
|
| 2017 |
Sidhom JW, Bessell CA, Havel JJ, Kosmides A, Chan TA, Schneck JP. ImmunoMap: A Bioinformatics Tool for T-Cell Repertoire Analysis. Cancer Immunology Research. PMID 29263161 DOI: 10.1158/2326-6066.Cir-17-0114 |
0.335 |
|
| 2017 |
Vandeven NA, Lewis CW, Makarov V, Riaz N, Paulson KG, Hippe DS, Bestick A, Doumani R, Marx T, Takagishi SR, Chan TA, Choi J, Nghiem P. Merkel cell carcinoma patients presenting without a primary lesion have elevated markers of immunity, higher tumor mutation burden and improved survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29246939 DOI: 10.1158/1078-0432.Ccr-17-1678 |
0.328 |
|
| 2017 |
Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, ... ... Chan TA, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science (New York, N.Y.). PMID 29217585 DOI: 10.1126/Science.Aao4572 |
0.317 |
|
| 2017 |
Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, ... ... Chan TA, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. PMID 29132146 DOI: 10.1038/Nature24462 |
0.324 |
|
| 2017 |
Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, Rizvi NA, Merghoub T, Levine AJ, Chan TA, Wolchok JD, Greenbaum BD. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. PMID 29132144 DOI: 10.1038/Nature24473 |
0.368 |
|
| 2017 |
Dalin MG, Katabi N, Persson M, Lee KW, Makarov V, Desrichard A, Walsh LA, West L, Nadeem Z, Ramaswami D, Havel JJ, Kuo F, Chadalavada K, Nanjangud GJ, Ganly I, ... ... Chan TA, et al. Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nature Communications. 8: 1197. PMID 29084941 DOI: 10.1038/S41467-017-01178-Z |
0.392 |
|
| 2017 |
Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL, Chowell D, ... ... Chan TA, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. PMID 29033130 DOI: 10.1016/J.Cell.2017.09.028 |
0.402 |
|
| 2017 |
Grinberg-Bleyer Y, Oh H, Desrichard A, Bhatt DM, Caron R, Chan TA, Schmid RM, Klein U, Hayden MS, Ghosh S. NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. Cell. 170: 1096-1108.e13. PMID 28886380 DOI: 10.1016/J.Cell.2017.08.004 |
0.336 |
|
| 2017 |
Walsh LA, Alvarez MJ, Sabio EY, Reyngold M, Makarov V, Mukherjee S, Lee KW, Desrichard A, Turcan Ş, Dalin MG, Rajasekhar VK, Chen S, Vahdat LT, Califano A, Chan TA. An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. Cell Reports. 20: 1623-1640. PMID 28813674 DOI: 10.1016/J.Celrep.2017.07.052 |
0.344 |
|
| 2017 |
Ibrahimpasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, Deraje Vasudeva S, Carlson D, Migliacci J, Knauf JA, Untch BR, Berger MF, Morris LG, Tuttle RM, Chan TA, et al. Genomic alterations in fatal forms of non-anaplastic thyroid cancer: Identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28634282 DOI: 10.1158/1078-0432.Ccr-17-1183 |
0.408 |
|
| 2017 |
Samstein RM, Chan TA. Dissecting microsatellite instability in colorectal cancer: one size does not fit all. Genome Medicine. 9: 45. PMID 28539127 DOI: 10.1186/S13073-017-0438-9 |
0.388 |
|
| 2017 |
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, ... ... Chan TA, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 169: 361. PMID 28388418 DOI: 10.1016/J.Cell.2017.03.036 |
0.516 |
|
| 2017 |
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, ... ... Chan TA, et al. Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 18: 46. PMID 28249590 DOI: 10.1186/S13059-017-1180-8 |
0.326 |
|
| 2017 |
Ascierto ML, Makohon-Moore A, Lipson EJ, Taube JM, McMiller TL, Berger AE, Fan J, Kaunitz G, Cottrell T, Kohutek Z, Favorov A, Makarov V, Riaz N, Chan TA, Cope L, et al. Transcriptional mechanisms of resistance to anti-PD-1 therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28193624 DOI: 10.1158/1078-0432.Ccr-17-0270 |
0.471 |
|
| 2017 |
Koncar RF, Chu Z, Romick-Rosendale LE, Wells SI, Chan TA, Qi X, Bahassi EM. PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. Oncotarget. PMID 28178660 DOI: 10.18632/Oncotarget.15015 |
0.353 |
|
| 2017 |
Voss MH, Kuo F, Chen D, Marker M, Patel P, Redzematovic A, Riaz N, Chan TA, Choueiri TK, Hsieh J, Motzer RJ, Hakimi AA. Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy. Journal of Clinical Oncology. 35: 4523-4523. DOI: 10.1200/Jco.2017.35.15_Suppl.4523 |
0.363 |
|
| 2017 |
Sidhom J, Bessell CA, Havel JJ, Chan TA, Schneck JP. Abstract 976: ImmunoMap: a novel bioinformatics tool for immune cell repertoire analysis Cancer Research. 77: 976-976. DOI: 10.1158/1538-7445.Am2017-976 |
0.367 |
|
| 2017 |
Ghamsari L, Flano E, Jacques J, Liu B, Yan Z, Alami A, Kelley C, Zhang T, Havel J, Makarov V, Merghoub T, Wolchok JD, Hellman M, Carroll P, Chan T, et al. Abstract 632: Genome-scale neoantigen screening using ATLAS™ prioritizes candidate antigens for immunotherapy in a non-small cell lung cancer patient Cancer Research. 77: 632-632. DOI: 10.1158/1538-7445.Am2017-632 |
0.403 |
|
| 2017 |
Chan TA, Riaz N, Havel JJ, Makarov V, Desrichard A, Sims JS, Hodi FS, Martín-Algarra S, Sharfman WH, Bhatia S, Hwu W, Gajewski TF, Slingluff CL, Kendall SM, Chang H, et al. Abstract 2988: Immunogenomic analyses of tumor cells and microenvironment in patients with advanced melanoma before and after treatment with nivolumab Cancer Research. 77: 2988-2988. DOI: 10.1158/1538-7445.Am2017-2988 |
0.358 |
|
| 2016 |
Ma J, Setton J, Morris L, Albornoz PB, Barker C, Lok BH, Sherman E, Katabi N, Beal K, Ganly I, Powell SN, Lee N, Chan TA, Riaz N. Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM. Oncotarget. PMID 28055970 DOI: 10.18632/Oncotarget.14400 |
0.441 |
|
| 2016 |
Rajappa P, Cobb WS, Vartanian E, Huang Y, Daly L, Hoffman C, Zhang J, Shen B, Yanowitch R, Garg K, Cisse B, Haddock S, Huse JT, Pisapia DJ, Chan TA, et al. Malignant astrocytic tumor progression potentiated by JAK-mediated recruitment of myeloid cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28039266 DOI: 10.1158/1078-0432.Ccr-16-1508 |
0.333 |
|
| 2016 |
Gong Y, Schumacher SE, Wu WH, Tang F, Beroukhim R, Chan TA. Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. Neoplasia (New York, N.Y.). 19: 75-83. PMID 28038320 DOI: 10.1016/J.Neo.2016.12.006 |
0.415 |
|
| 2016 |
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, ... ... Chan TA, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 17: 231. PMID 27855702 DOI: 10.1186/S13059-016-1092-Z |
0.387 |
|
| 2016 |
Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG. The head and neck cancer immune landscape and its immunotherapeutic implications. Jci Insight. 1: e89829. PMID 27777979 DOI: 10.1172/Jci.Insight.89829 |
0.374 |
|
| 2016 |
Marusyk A, Tabassum D, Janiszewska M, Place A, Trinh A, Rozhok AI, Pyne S, Guerrierro J, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, et al. Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes. Cancer Research. PMID 27671678 DOI: 10.1158/0008-5472.Can-16-1457 |
0.541 |
|
| 2016 |
Riaz N, Havel JJ, Kendall SM, Makarov V, Walsh LA, Desrichard A, Weinhold N, Chan TA. Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nature Genetics. PMID 27668655 DOI: 10.1038/Ng.3677 |
0.364 |
|
| 2016 |
Morris LG, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, Wong RJ, Lee NY, Sherman EJ, Baxi SS, Ganly I, Singh B, Shah JP, Shaha AR, Boyle JO, ... ... Chan TA, et al. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. Jama Oncology. PMID 27442865 DOI: 10.1001/Jamaoncol.2016.1790 |
0.34 |
|
| 2016 |
Hellmann M, Rizvi N, Wolchok JD, Chan TA. Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Molecular & Cellular Oncology. 3: e1048929. PMID 27308563 DOI: 10.1080/23723556.2015.1048929 |
0.352 |
|
| 2016 |
Roy DM, Walsh LA, Desrichard A, Huse JT, Wu W, Gao J, Bose P, Lee W, Chan TA. Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. Cancer Cell. 29: 737-50. PMID 27165745 DOI: 10.1016/J.Ccell.2016.03.025 |
0.362 |
|
| 2016 |
Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro-Oncology. PMID 27116977 DOI: 10.1093/Neuonc/Now061 |
0.348 |
|
| 2016 |
Mandal R, Chan TA. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discovery. PMID 27107038 DOI: 10.1158/2159-8290.Cd-16-0146 |
0.413 |
|
| 2016 |
Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, Wang Q, Armenia J, West L, Dogan S, Wang L, Ramaswami D, Ho AL, Ganly I, Solit D, ... ... Chan TA, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27103403 DOI: 10.1158/1078-0432.Ccr-16-0637 |
0.409 |
|
| 2016 |
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, ... ... Chan TA, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 164: 1073. PMID 27064190 DOI: 10.1016/J.Cell.2015.10.020 |
0.516 |
|
| 2016 |
Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in the response to immune checkpoint blockade. International Immunology. PMID 27048318 DOI: 10.1093/Intimm/Dxw019 |
0.383 |
|
| 2016 |
Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, et al. Corticosteroids compromise survival in glioblastoma. Brain : a Journal of Neurology. PMID 27020328 DOI: 10.1093/Brain/Aww046 |
0.367 |
|
| 2016 |
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, ... ... Chan TA, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, N.Y.). PMID 26940869 DOI: 10.1126/Science.Aaf1490 |
0.408 |
|
| 2016 |
Morris LG, Riaz N, Desrichard A, Şenbabaoğlu Y, Hakimi AA, Makarov V, Reis-Filho JS, Chan TA. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget. PMID 26840267 DOI: 10.18632/Oncotarget.7067 |
0.444 |
|
| 2016 |
Chowell D, Chan TA. The immunogenicity of cancer mutations and implications for T cell therapy Translational Cancer Research. 5. DOI: 10.21037/10163 |
0.413 |
|
| 2016 |
Song D, Swartz MH, Biesecker SG, Borda F, Shah RR, Emtage P, Wierda WG, Cooper LJN, Chan T. Chimeric Antigen Receptor-Modified T Cells for the Treatment of Acute Myeloid Leukemia Expressing CD33 Blood. 128: 4058-4058. DOI: 10.1182/Blood.V128.22.4058.4058 |
0.303 |
|
| 2016 |
Chowell D, Krishna S, Snyder A, Vladimir M, Chan TA, Anderson KS. Abstract A116: A predictive model to identify immunogenic neoepitopes in patients with melanoma treated with CTLA-4 blockade Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A116 |
0.404 |
|
| 2016 |
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Wolchok J, Zahnow CA, Mergoub T, ... Chan TA, et al. Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-B32 |
0.426 |
|
| 2016 |
Rao A, Zhang X, Deibert C, Sette P, Chan T, Grandi P, Amankulor N. Abstract 3235: IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligands Cancer Research. 76: 3235-3235. DOI: 10.1158/1538-7445.Am2016-3235 |
0.384 |
|
| 2015 |
Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, Stafstrom K, Moshiri A, Yelistratova L, Levinsohn J, Chan TA, Nghiem P, Lifton RP, Choi J. Mutational landscape of MCPyV-positive and MCPyV-negative merkel cell carcinomas with implications for immunotherapy. Oncotarget. PMID 26655088 DOI: 10.18632/Oncotarget.6494 |
0.438 |
|
| 2015 |
Bai H, Harmancı AS, Erson-Omay EZ, Li J, Coşkun S, Simon M, Krischek B, Özduman K, Omay SB, Sorensen EA, Turcan Ş, Bakırcığlu M, Carrión-Grant G, Murray PB, Clark VE, ... ... Chan TA, et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nature Genetics. PMID 26618343 DOI: 10.1038/Ng.3457 |
0.4 |
|
| 2015 |
Desrichard A, Snyder A, Chan TA. Cancer Neoantigens and Applications for Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26515495 DOI: 10.1158/1078-0432.Ccr-14-3175 |
0.364 |
|
| 2015 |
Snyder A, Makarov V, Hellmann M, Rizvi N, Merghoub T, Wolchok JD, Chan TA. Genetics and immunology: reinvigorated. Oncoimmunology. 4: e1029705. PMID 26451299 DOI: 10.1080/2162402X.2015.1029705 |
0.33 |
|
| 2015 |
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Buhu S, Slamon DJ, Wolchok JD, Pardoll DM, ... ... Chan TA, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 162: 974-86. PMID 26317466 DOI: 10.1016/J.Cell.2015.07.011 |
0.575 |
|
| 2015 |
Peyser ND, Du Y, Li H, Lui V, Xiao X, Chan TA, Grandis JR. Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. Plos One. 10: e0135750. PMID 26267899 DOI: 10.1371/Journal.Pone.0135750 |
0.424 |
|
| 2015 |
Martelotto LG, De Filippo MR, Ng CK, Natrajan R, Fuhrmann L, Cyrta J, Piscuoglio S, Wen HC, Lim RS, Shen R, Schultheis AM, Wen YH, Edelweiss M, Mariani O, Stenman G, ... Chan TA, et al. Genomic landscape of adenoid cystic carcinoma of the breast. The Journal of Pathology. PMID 26095796 DOI: 10.1002/Path.4573 |
0.357 |
|
| 2015 |
Topalian SL, Wolchok JD, Chan TA, Mellman I, Palucka K, Banchereau J, Rosenberg SA, Dane Wittrup K. Immunotherapy: The path to win the war on cancer? Cell. 161: 185-6. PMID 26042237 DOI: 10.1016/J.Cell.2015.03.045 |
0.33 |
|
| 2015 |
Havel JJ, Chan TA. High-resolution genomic analysis: the tumor-immune interface comes into focus. Genome Biology. 16: 65. PMID 25853850 DOI: 10.1186/S13059-015-0631-3 |
0.321 |
|
| 2015 |
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, ... ... Chan TA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.). 348: 124-8. PMID 25765070 DOI: 10.1126/Science.Aaa1348 |
0.433 |
|
| 2015 |
Snyder A, Chan TA. Immunogenic peptide discovery in cancer genomes. Current Opinion in Genetics & Development. 30: 7-16. PMID 25588790 DOI: 10.1016/J.Gde.2014.12.003 |
0.353 |
|
| 2015 |
Walsh LA, Roy DM, Reyngold M, Giri D, Snyder A, Turcan S, Badwe CR, Lyman J, Bromberg J, King TA, Chan TA. RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch. Oncogene. 34: 2189-203. PMID 24931164 DOI: 10.1038/Onc.2014.175 |
0.378 |
|
| 2015 |
Ahuja A, Nathanson T, Rubinsteyn A, Snyder A, Hellman M, Chan T, Merghoub T, Wolchok J, Hammerbacher J. Neoantigen homology and predicting response to immune checkpoint blockade in cancer F1000research. 4. DOI: 10.7490/F1000Research.1110758.1 |
0.331 |
|
| 2015 |
Omuro AMP, Zehir A, Cheng DT, Berger MF, Hyman DM, Solit DB, Baselga J, Ladanyi M, Arcila ME, Hameed M, Sabbatini P, DeAngelis LM, Gutin PH, Rosenblum M, Mellinghoff IK, ... ... Chan TA, et al. Is Next Generation Sequencing (NGS) Ready for Routine Clinical Practice in Gliomas? Results of a Prospective Study Utilizing the MSK-IMPACT Assay Journal of Clinical Oncology. 33: 2057-2057. DOI: 10.1200/Jco.2015.33.15_Suppl.2057 |
0.359 |
|
| 2015 |
Roy DM, Walsh LA, Desrichard A, Gao J, Bose P, Huse JT, Lee W, Chan TA. Abstract LB-169: Multidimensional genomic dissection of chromosome 9p in glioma Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-169 |
0.384 |
|
| 2015 |
Danussi C, Bose P, Parthasarathy P, Turcan S, Picketts D, Chan T, Huse J. Epig-06Atrx Deficiency Promotes Migratory Behavior In Glioma Cells Of Origin By Dysregulating Genome-Wide Chromatin Accessibility And Modulating Transcriptional Programs. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov214.06 |
0.373 |
|
| 2014 |
Riaz N, Morris LG, Lee W, Chan TA. Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes & Diseases. 1: 75-86. PMID 25642447 DOI: 10.1016/J.Gendis.2014.07.002 |
0.4 |
|
| 2014 |
Gong Y, Chan TA. Molecular mechanisms orchestrating cyclin stability. Cell Cycle (Georgetown, Tex.). 13: 2487-8. PMID 25486187 DOI: 10.4161/15384101.2014.946376 |
0.334 |
|
| 2014 |
Barker CA, Chang M, Beal K, Chan TA. Survival of patients treated with radiation therapy for anaplastic astrocytoma. Radiology and Oncology. 48: 381-6. PMID 25435851 DOI: 10.2478/Raon-2014-0019 |
0.322 |
|
| 2014 |
Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost. Nature. 515: 496-8. PMID 25428495 DOI: 10.1038/515496A |
0.341 |
|
| 2014 |
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, ... ... Chan TA, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine. 371: 2189-99. PMID 25409260 DOI: 10.1056/Nejmoa1406498 |
0.372 |
|
| 2014 |
Yang TJ, Oh JH, Folkert MR, Gupta G, Shi W, Zhang Z, Morikawa A, Seidman A, Brennan C, Yamada Y, Chan TA, Beal K. Outcomes and prognostic factors in women with 1 to 3 breast cancer brain metastases treated with definitive stereotactic radiosurgery. International Journal of Radiation Oncology, Biology, Physics. 90: 518-25. PMID 25194669 DOI: 10.1016/J.Ijrobp.2014.06.063 |
0.306 |
|
| 2014 |
Ortiz B, White JR, Wu WH, Chan TA. Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis. Oncotarget. 5: 6976-82. PMID 25138050 DOI: 10.18632/Oncotarget.2106 |
0.35 |
|
| 2014 |
Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, Drobnjak M, Vahdat LT, Lee W, Chan TA. Remodeling of the methylation landscape in breast cancer metastasis. Plos One. 9: e103896. PMID 25083786 DOI: 10.1371/Journal.Pone.0103896 |
0.333 |
|
| 2014 |
Ortiz B, Fabius AW, Wu WH, Pedraza A, Brennan CW, Schultz N, Pitter KL, Bromberg JF, Huse JT, Holland EC, Chan TA. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America. 111: 8149-54. PMID 24843164 DOI: 10.1073/Pnas.1401952111 |
0.371 |
|
| 2014 |
Gong Y, Zack TI, Morris LG, Lin K, Hukkelhoven E, Raheja R, Tan IL, Turcan S, Veeriah S, Meng S, Viale A, Schumacher SE, Palmedo P, Beroukhim R, Chan TA. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nature Genetics. 46: 588-94. PMID 24793136 DOI: 10.1038/Ng.2981 |
0.357 |
|
| 2014 |
Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein & Cell. 5: 265-96. PMID 24622842 DOI: 10.1007/S13238-014-0031-6 |
0.427 |
|
| 2014 |
Ung N, Putoczki TL, Stylli SS, Ng I, Mariadason JM, Chan TA, Zhu HJ, Luwor RB. Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biology & Therapy. 15: 623-32. PMID 24556630 DOI: 10.4161/Cbt.28179 |
0.357 |
|
| 2014 |
Leder K, Pitter K, Laplant Q, Hambardzumyan D, Ross BD, Chan TA, Holland EC, Michor F. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell. 156: 603-16. PMID 24485463 DOI: 10.1016/J.Cell.2013.12.029 |
0.327 |
|
| 2014 |
Brennan C, Yang TJ, Hilden P, Zhang Z, Chan K, Yamada Y, Chan TA, Lymberis SC, Narayana A, Tabar V, Gutin PH, Ballangrud Ã…, Lis E, Beal K. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. International Journal of Radiation Oncology, Biology, Physics. 88: 130-6. PMID 24331659 DOI: 10.1016/J.Ijrobp.2013.09.051 |
0.304 |
|
| 2014 |
Silber J, Harinath G, Parthasarathy PT, Fabius AWM, Turcan S, Chan TA, Huse JT. Abstract 521: Glioma-associated IDH mutation induces miR-34a repression and stem cell-like physiology through enhanced PDGF signaling Cancer Research. 74: 521-521. DOI: 10.1158/1538-7445.Am2014-521 |
0.312 |
|
| 2013 |
Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 4: 1729-36. PMID 24077826 DOI: 10.18632/Oncotarget.1412 |
0.404 |
|
| 2013 |
Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, Riggins GJ. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 4: 1737-47. PMID 24077805 DOI: 10.18632/Oncotarget.1408 |
0.375 |
|
| 2013 |
Turcan S, Chan TA. MAPping the genomic landscape of low-grade pediatric gliomas. Nature Genetics. 45: 847-9. PMID 23892663 DOI: 10.1038/Ng.2706 |
0.312 |
|
| 2013 |
Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. The Journal of Clinical Endocrinology and Metabolism. 98: E1562-6. PMID 23833040 DOI: 10.1210/Jc.2013-2383 |
0.398 |
|
| 2013 |
Tönjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai AH, Karra D, Piro RM, Felsberg J, Addington A, Lemke D, Weibrecht I, Hovestadt V, ... ... Chan TA, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nature Medicine. 19: 901-8. PMID 23793099 DOI: 10.1038/Nm.3217 |
0.33 |
|
| 2013 |
Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, ... ... Chan TA, et al. The mutational landscape of adenoid cystic carcinoma. Nature Genetics. 45: 791-8. PMID 23685749 DOI: 10.1038/Ng.2643 |
0.406 |
|
| 2013 |
Ho AS, Turcan S, Chan TA. Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. Oncotargets and Therapy. 6: 223-32. PMID 23569385 DOI: 10.2147/Ott.S34680 |
0.355 |
|
| 2013 |
Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, ... ... Chan TA, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (New York, N.Y.). 340: 626-30. PMID 23558169 DOI: 10.1126/Science.1236062 |
0.391 |
|
| 2013 |
Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, Socci N, Kannan K, Mo Q, Fagin JA, Chan TA. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. The Journal of Clinical Endocrinology and Metabolism. 98: E962-72. PMID 23543667 DOI: 10.1210/Jc.2012-3539 |
0.373 |
|
| 2013 |
Morris LG, Ramaswami D, Chan TA. The FAT epidemic: a gene family frequently mutated across multiple human cancer types. Cell Cycle (Georgetown, Tex.). 12: 1011-2. PMID 23493187 DOI: 10.4161/Cc.24305 |
0.384 |
|
| 2013 |
Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan ?, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, ... ... Chan TA, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics. 45: 253-61. PMID 23354438 DOI: 10.1038/Ng.2538 |
0.426 |
|
| 2013 |
Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, ... ... Chan TA, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. The Journal of Clinical Endocrinology and Metabolism. 98: E364-9. PMID 23264394 DOI: 10.1210/Jc.2012-2703 |
0.747 |
|
| 2013 |
Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, ... ... Chan TA, et al. CELL BIOLOGY AND SIGNALING Neuro-Oncology. 15: iii12-iii31. DOI: 10.1093/Neuonc/Not174 |
0.436 |
|
| 2012 |
Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 3: 1194-203. PMID 23104868 DOI: 10.18632/Oncotarget.689 |
0.369 |
|
| 2012 |
Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science (New York, N.Y.). 338: 221. PMID 22923433 DOI: 10.1126/Science.1226344 |
0.372 |
|
| 2012 |
Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, Chan TA, Saltz LB, Weiser M, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2956-62. PMID 22665543 DOI: 10.1200/Jco.2011.38.2994 |
0.387 |
|
| 2012 |
Jeschke J, Van Neste L, Glöckner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, Chan TA, Cope L, Hooker CM, Schuebel KE, Gabrielson E, Winterpacht A, et al. Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics. 7: 701-9. PMID 22647880 DOI: 10.4161/Epi.20445 |
0.337 |
|
| 2012 |
Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 483: 474-8. PMID 22343901 DOI: 10.1038/Nature10860 |
0.319 |
|
| 2012 |
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, ... ... Chan TA, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 483: 479-83. PMID 22343889 DOI: 10.1038/Nature10866 |
0.389 |
|
| 2012 |
Dana CE, Glauber KM, Chan TA, Bridge DM, Steele RE. Incorporation of a horizontally transferred gene into an operon during cnidarian evolution. Plos One. 7: e31643. PMID 22328943 DOI: 10.1371/Journal.Pone.0031643 |
0.42 |
|
| 2012 |
Meehan M, Parthasarathi L, Moran N, Jefferies CA, Foley N, Lazzari E, Murphy D, Ryan J, Ortiz B, Fabius AW, Chan TA, Stallings RL. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Molecular Cancer. 11: 6. PMID 22305495 DOI: 10.1186/1476-4598-11-6 |
0.343 |
|
| 2012 |
Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Chan TA, Rizvi NA, Azzoli CG, Riely GJ, Kris MG, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1138-45. PMID 22228633 DOI: 10.1158/1078-0432.Ccr-11-2059 |
0.318 |
|
| 2012 |
Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 382-5. PMID 22089116 DOI: 10.1097/Jto.0B013E3182398E4F |
0.326 |
|
| 2011 |
Morris LG, Chan TA. Resistance to EGFR inhibitors: molecular determinants and the enigma of head and neck cancer. Oncotarget. 2: 894-5. PMID 22248868 DOI: 10.18632/Oncotarget.407 |
0.363 |
|
| 2011 |
Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, ... Chan TA, et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America. 108: 19024-9. PMID 22065749 DOI: 10.1073/Pnas.1111963108 |
0.387 |
|
| 2011 |
Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, ... ... Chan TA, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Science Translational Medicine. 3: 75ra25. PMID 21430268 DOI: 10.1126/Scitranslmed.3001875 |
0.351 |
|
| 2011 |
Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A, Chan TA, Comen E, Andrade VP, Kim SW, King TA, Hudis CA, Norton L, Hicks J, Massagué J, et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes & Development. 25: 226-31. PMID 21289068 DOI: 10.1101/Gad.1974211 |
0.348 |
|
| 2011 |
Morris LG, Ganly I, Taylor B, Singh B, Viale A, Heguy A, Chan TA. Abstract 3911: Functional copy number alterations (CNAS) in oral cancer Cancer Research. 71: 3911-3911. DOI: 10.1158/1538-7445.Am2011-3911 |
0.36 |
|
| 2011 |
Ganly I, Morris L, Taylor B, Singh B, Viale A, Chan T. P124. Dysregulation of the PI3K/AKT/MTOR pathway by mutation and copy number alteration in oral cavity squamous cell cancer Oral Oncology. 47. DOI: 10.1016/J.Oraloncology.2011.06.367 |
0.426 |
|
| 2010 |
Morris LG, Veeriah S, Chan TA. Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene. 29: 3453-64. PMID 20418918 DOI: 10.1038/Onc.2010.127 |
0.407 |
|
| 2010 |
Veeriah S, Morris L, Solit D, Chan TA. The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. Cell Cycle (Georgetown, Tex.). 9: 1451-2. PMID 20372088 DOI: 10.4161/Cc.9.8.11583 |
0.451 |
|
| 2010 |
Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, ... ... Chan TA, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature Genetics. 42: 77-82. PMID 19946270 DOI: 10.1038/Ng.491 |
0.386 |
|
| 2010 |
Saggese M, Thodima V, Heguy A, Chan TA, Chaganti RSK. Abstract 4924: Gene-specific hyper and hypomethylation in follicular lymphoma progression Cancer Research. 70: 4924-4924. DOI: 10.1158/1538-7445.Am10-4924 |
0.325 |
|
| 2010 |
Morris LG, Ganly I, Heguy A, Chan TA. Abstract 2222: Mutational and copy number analysis of the PI3K/Akt/mTOR pathway in oral cavity squamous cell carcinoma Cellular and Molecular Biology. 70: 2222-2222. DOI: 10.1158/1538-7445.Am10-2222 |
0.324 |
|
| 2010 |
Pietanza MC, Travis WD, Chan TA, Ginsberg MS, Kris AHMG, Krug LM. Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer Pancreas. 39: 279. DOI: 10.1097/01.Mpa.0000363940.51906.5A |
0.302 |
|
| 2009 |
Chan TA, Heguy A. The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function. Cell Cycle (Georgetown, Tex.). 8: 3063-4. PMID 19755842 DOI: 10.4161/Cc.8.19.9455 |
0.341 |
|
| 2009 |
Meng S, Arbit T, Veeriah S, Mellinghoff IK, Fang F, Vivanco I, Rohle D, Chan TA. 14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell Cycle (Georgetown, Tex.). 8: 2238-46. PMID 19502805 DOI: 10.4161/Cc.8.14.8998 |
0.342 |
|
| 2009 |
Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, ... ... Chan TA, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/Pnas.0900571106 |
0.439 |
|
| 2009 |
Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruïne AP, Smits KM, Khalid-de Bakker CA, Jonkers DM, Stockbrügger RW, Meijer GA, Oort FA, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Research. 69: 4691-9. PMID 19435926 DOI: 10.1158/0008-5472.Can-08-0142 |
0.321 |
|
| 2008 |
Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. Plos Medicine. 5: e114. PMID 18507500 DOI: 10.1371/Journal.Pmed.0050114 |
0.436 |
|
| 2008 |
Rimner A, Ho A, Ahuja N, Schuebel K, Baylin S, Gerald W, Chan T. Syne1 Promoter Hypermethylation as a Predictor of Tumor Aggressiveness in Primary Breast Cancer International Journal of Radiation Oncology*Biology*Physics. 72: S681-S682. DOI: 10.1016/J.Ijrobp.2008.06.563 |
0.339 |
|
| 2007 |
Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, van Engeland M, Ting AH, Jair K, Yu W, Toyota M, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. Plos Genetics. 3: 1709-23. PMID 17892325 DOI: 10.1371/Journal.Pgen.0030157 |
0.42 |
|
| 2006 |
Chan TA. Prostaglandins and the colon cancer connection. Trends in Molecular Medicine. 12: 240-4. PMID 16650804 DOI: 10.1016/J.Molmed.2006.04.006 |
0.34 |
|
| 2003 |
Chan TA. Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention. Current Cancer Drug Targets. 3: 455-63. PMID 14683503 DOI: 10.2174/1568009033481723 |
0.336 |
|
| 2002 |
Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW. Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proceedings of the National Academy of Sciences of the United States of America. 99: 8265-70. PMID 12060769 DOI: 10.1073/Pnas.082240999 |
0.45 |
|
| 2002 |
Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. The Lancet. Oncology. 3: 166-74. PMID 11902503 DOI: 10.1016/S1470-2045(02)00680-0 |
0.325 |
|
| 2001 |
Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nature Medicine. 7: 1111-7. PMID 11590433 DOI: 10.1038/Nm1001-1111 |
0.752 |
|
| 2001 |
Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RAJ, Kinzler KW, Vogelstein B. Erratum: Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells (Nature Medicine (2001) 7 (1111-1117)) Nature Medicine. 7. DOI: 10.1038/Nm1101-1255A |
0.743 |
|
| 2000 |
Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes & Development. 14: 1584-8. PMID 10887152 DOI: 10.1101/Gad.14.13.1584 |
0.501 |
|
| 2000 |
Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 97: 6049-54. PMID 10811911 DOI: 10.1073/Pnas.100566997 |
0.356 |
|
| 1999 |
He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 99: 335-45. PMID 10555149 DOI: 10.1016/S0092-8674(00)81664-5 |
0.489 |
|
| 1999 |
Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 401: 616-20. PMID 10524633 DOI: 10.1038/44188 |
0.496 |
|
| 1998 |
Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 95: 681-6. PMID 9435252 DOI: 10.1073/Pnas.95.2.681 |
0.504 |
|
| 1996 |
Da Costa LT, Jen J, He TC, Chan TA, Kinzler KW, Vogelstein B. Converting cancer genes into killer genes. Proceedings of the National Academy of Sciences of the United States of America. 93: 4192-6. PMID 8633039 DOI: 10.1073/Pnas.93.9.4192 |
0.506 |
|
| 1995 |
Suzuki H, Zhou X, Yin J, Lei J, Jiang HY, Suzuki Y, Chan T, Hannon GJ, Mergner WJ, Abraham JM, Melzer SJ. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers Human Molecular Genetics. 4: 1883-1887. PMID 8595411 DOI: 10.1093/Hmg/4.10.1883 |
0.426 |
|
| 1994 |
Chan TA, Chu CA, Rauen KA, Kroiher M, Tatarewicz SM, Steele RE. Identification of a gene encoding a novel protein-tyrosine kinase containing SH2 domains and ankyrin-like repeats Oncogene. 9: 1253-1259. PMID 8134129 |
0.409 |
|
| Show low-probability matches. |